Landmark Studies

Glaucoma Therapy Delivers Great Patient and Financial Value

The cost-utility analysis associated with glaucoma therapy.

Gary C. Brown, MD, MBA; Joshua D. Stein, MD, MSc, MS; Melissa M. Brown, MD, MN, MBA; Richard P. Wilson, MD; and George L. Spaeth, MD

Landmark Studies

Costs and Financial Gain Associated With Glaucoma Therapy

Ophthalmic interventions deliver significant patient and financial value.

Gary C. Brown, MD, MBA; Melissa M. Brown, MD, MN, MBA; Joshua D. Stein, MD, MSc, MS; Richard P. Wilson, MD; and George L. Spaeth, MD

Landmark Studies

Measuring the Impact of Glaucoma and the Value of Treatment

A primer on value-based medicine.

Gary C. Brown, MD, MBA; Melissa M. Brown, MD, MN, MBA; Joshua D. Stein, MD, MSc, MS; Richard P. Wilson, MD; and George L. Spaeth, MD

Landmark Studies

Questions and Answers on AGIS Statistics

Jeffrey Tennant, MD; Douglas E. Gaasterland, MD; E. Kenneth Sullivan, PhD; and Paul VanVeldhuisen, PhD

Landmark Studies

Take-Home Messages From the Advanced Glaucoma Intervention Study

Leon W. Herndon, MD, and Daniel B. Moore, MD

Landmark Studies

Key Findings From the Tube Versus Trabeculectomy Study

Steven R. Sarkisian Jr, MD

Landmark Studies

The Collaborative Initial Glaucoma Treatment Study—What We Have Learned so Far

Jess T. Whitson, MD

Landmark Studies

Optic Discs of the Ocular Hypertension Treatment Study

LINDA M. ZANGWILL, PHD; FELIPE A. MEDEIROS, MD, PHD; AND ROBERT N. WEINREB, MD

Landmark Studies

Fields of OHTS: The Ocular Hypertension Treatment Study

Chris A. Johnson, PhD; John L. Keltner, MD; and Paul H. Artes, PhD

Landmark Studies

The Ocular Hypertension Treatment Study

MICHAEL A. KASS, MD

Landmark Studies

Learn to Ask Yourself the Essential Questions

RONALD L. FELLMAN, MD